498 related articles for article (PubMed ID: 25797172)
21. Anti-BP230 IgE autoantibodies in bullous pemphigoid intraindividually correlate with disease activity.
Emtenani S; Linnemann BE; Recke A; von Georg A; Goletz S; Schmidt E; van Beek N
J Dermatol Sci; 2024 May; 114(2):64-70. PubMed ID: 38582700
[TBL] [Abstract][Full Text] [Related]
22. In vivo analysis of IgE autoantibodies in bullous pemphigoid: a study of 100 cases.
Moriuchi R; Nishie W; Ujiie H; Natsuga K; Shimizu H
J Dermatol Sci; 2015 Apr; 78(1):21-5. PubMed ID: 25724363
[TBL] [Abstract][Full Text] [Related]
23. Bullous pemphigoid (BP) patients with selective IgG autoreactivity against BP230: Review of a rare but valuable cohort with impact on the comprehension of the pathogenesis of BP.
Ramcke T; Vicari E; Bolduan V; Enk A; Hadaschik E
J Dermatol Sci; 2022 Feb; 105(2):72-79. PubMed ID: 34930674
[TBL] [Abstract][Full Text] [Related]
24. Role of BP230 autoantibodies in bullous pemphigoid.
Shih YC; Wang B; Yuan H; Zheng J; Pan M
J Dermatol; 2020 Apr; 47(4):317-326. PubMed ID: 32048350
[TBL] [Abstract][Full Text] [Related]
25. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.
Fairley JA; Baum CL; Brandt DS; Messingham KA
J Allergy Clin Immunol; 2009 Mar; 123(3):704-5. PubMed ID: 19152970
[No Abstract] [Full Text] [Related]
26. Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies.
Messingham KN; Pietras TA; Fairley JA
G Ital Dermatol Venereol; 2012 Jun; 147(3):251-7. PubMed ID: 22648326
[TBL] [Abstract][Full Text] [Related]
27. Immune Reaction to Type XVII Collagen Induces Intramolecular and Intermolecular Epitope Spreading in Experimental Bullous Pemphigoid Models.
Ujiie H; Yoshimoto N; Natsuga K; Muramatsu K; Iwata H; Nishie W; Shimizu H
Front Immunol; 2019; 10():1410. PubMed ID: 31275329
[TBL] [Abstract][Full Text] [Related]
28. Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.
Messingham KA; Holahan HM; Fairley JA
Immunol Res; 2014 Aug; 59(1-3):273-8. PubMed ID: 24845463
[TBL] [Abstract][Full Text] [Related]
29. Bullous pemphigoid autoantibodies directly induce blister formation without complement activation.
Ujiie H; Sasaoka T; Izumi K; Nishie W; Shinkuma S; Natsuga K; Nakamura H; Shibaki A; Shimizu H
J Immunol; 2014 Nov; 193(9):4415-28. PubMed ID: 25261486
[TBL] [Abstract][Full Text] [Related]
30. Immunoadsorber for specific apheresis of autoantibodies in the treatment of bullous pemphigoid.
Mersmann M; Dworschak J; Ebermann K; Komorowski L; Schlumberger W; Stöcker W; Zillikens D; Probst C; Schmidt E
Arch Dermatol Res; 2016 Jan; 308(1):31-8. PubMed ID: 26498290
[TBL] [Abstract][Full Text] [Related]
31. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid.
Roussel A; Benichou J; Randriamanantany ZA; Gilbert D; Drenovska K; Houivet E; Tron F; Joly P
Arch Dermatol; 2011 Mar; 147(3):293-8. PubMed ID: 21422336
[TBL] [Abstract][Full Text] [Related]
32. Pathogenesis of bullous pemphigoid.
Ujiie H; Nishie W; Shimizu H
Immunol Allergy Clin North Am; 2012 May; 32(2):207-15, v. PubMed ID: 22560134
[TBL] [Abstract][Full Text] [Related]
33. Detection of anti-BP180NC16a and anti-BP230 autoantibodies in blister fluid of patients with bullous pemphigoid: the first survey in Greece.
Patsatsi A; Vyzantiadis TA; Devliotou-Panagiotidou D; Chrysomallis F; Sotiriadis D
Clin Exp Dermatol; 2008 Mar; 33(2):183-5. PubMed ID: 18093242
[TBL] [Abstract][Full Text] [Related]
34. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients.
Charneux J; Lorin J; Vitry F; Antonicelli F; Reguiai Z; Barbe C; Tabary T; Grange F; Bernard P
Arch Dermatol; 2011 Mar; 147(3):286-91. PubMed ID: 21422334
[TBL] [Abstract][Full Text] [Related]
35. BP180- and BP230-specific IgG autoantibodies in pruritic disorders of the elderly: a preclinical stage of bullous pemphigoid?
Schmidt T; Sitaru C; Amber K; Hertl M
Br J Dermatol; 2014 Aug; 171(2):212-9. PubMed ID: 24601973
[TBL] [Abstract][Full Text] [Related]
36. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles.
Tanaka M; Hashimoto T; Dykes PJ; Nishikawa T
Clin Exp Dermatol; 1996 Jan; 21(1):23-7. PubMed ID: 8689764
[TBL] [Abstract][Full Text] [Related]
37. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230.
Skaria M; Jaunin F; Hunziker T; Riou S; Schumann H; Bruckner-Tuderman L; Hertl M; Bernard P; Saurat JH; Favre B; Borradori L
J Invest Dermatol; 2000 May; 114(5):998-1004. PubMed ID: 10771483
[TBL] [Abstract][Full Text] [Related]
38. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid.
Fairley JA; Fu CL; Giudice GJ
J Invest Dermatol; 2005 Sep; 125(3):467-72. PubMed ID: 16117787
[TBL] [Abstract][Full Text] [Related]
39. Noncollagenous 16A domain of type XVII collagen-reactive CD4+ T cells play a pivotal role in the development of active disease in experimental bullous pemphigoid model.
Ujiie H; Shibaki A; Nishie W; Shinkuma S; Moriuchi R; Qiao H; Shimizu H
Clin Immunol; 2012 Feb; 142(2):167-75. PubMed ID: 22044750
[TBL] [Abstract][Full Text] [Related]
40. What's new in bullous pemphigoid.
Ujiie H; Shibaki A; Nishie W; Shimizu H
J Dermatol; 2010 Mar; 37(3):194-204. PubMed ID: 20507382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
